Published in Arthritis Rheum on April 01, 2010
Novel aspects of Sjögren's syndrome in 2012. BMC Med (2013) 1.44
Advances in human B cell phenotypic profiling. Front Immunol (2012) 1.41
Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome. Blood (2012) 1.27
Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol (2012) 1.19
Advances in understanding the pathogenesis of primary Sjögren's syndrome. Nat Rev Rheumatol (2013) 1.16
Immunotherapy of systemic sclerosis. Immunotherapy (2010) 1.03
Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome--a double blind, randomised clinical trial. PLoS One (2012) 1.00
Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther (2013) 0.93
Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther (2011) 0.93
Sjögren's syndrome: still not fully understood disease. Rheumatol Int (2014) 0.93
Temporal changes in salivary glands of non-obese diabetic mice as a model for Sjögren's syndrome. Oral Dis (2011) 0.92
Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome. Arthritis Res Ther (2011) 0.91
What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis? Arthritis Res Ther (2011) 0.91
Sjögren syndrome. CMAJ (2014) 0.88
Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum (2013) 0.86
A five-year prospective study of fatigue in primary Sjögren's syndrome. Arthritis Res Ther (2011) 0.85
Targeting the splicing of mRNA in autoimmune diseases: BAFF inhibition in Sjögren's syndrome as a proof of concept. Mol Ther (2013) 0.84
Understanding the role of B cells in atherosclerosis: potential clinical implications. Expert Rev Clin Immunol (2013) 0.82
TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice. Oral Dis (2011) 0.82
Clinical significance of chronic hepatitis B virus infection in patients with primary Sjögren's syndrome. Clin Rheumatol (2011) 0.81
B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment. PLoS One (2015) 0.81
Efficacy and safety of rituximab in rheumatic diseases. Wien Med Wochenschr (2015) 0.81
Cellular targeting in autoimmunity. Curr Allergy Asthma Rep (2012) 0.80
Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol (2017) 0.80
Monocytes from Sjögren's syndrome patients display increased vasoactive intestinal peptide receptor 2 expression and impaired apoptotic cell phagocytosis. Clin Exp Immunol (2014) 0.79
The immune factors involved in the pathogenesis, diagnosis, and treatment of Sjogren's syndrome. Clin Dev Immunol (2013) 0.79
STAT-5 is activated constitutively in T cells, B cells and monocytes from patients with primary Sjögren's syndrome. Clin Exp Immunol (2015) 0.78
SF-36 total score as a single measure of health-related quality of life: Scoping review. SAGE Open Med (2016) 0.78
Rituximab-mediated Raf kinase inhibitor protein induction modulates NF-κB in Sjögren syndrome. Immunology (2014) 0.77
Pharmacotherapy of scleritis: current paradigms and future directions. Expert Opin Pharmacother (2013) 0.77
Use of biologic agents in ocular manifestations of rheumatic disease. Int J Rheumatol (2011) 0.77
Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED). BMC Ophthalmol (2015) 0.77
B Cells and Atherosclerosis. Am J Physiol Heart Circ Physiol (2017) 0.77
Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome? PLoS One (2015) 0.76
Salivary Secretory Disorders, Inducing Drugs, and Clinical Management. Int J Med Sci (2015) 0.76
T Helper 17 Cells in Primary Sjögren's Syndrome. J Clin Med (2017) 0.76
B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease. Expert Rev Hematol (2016) 0.75
Association of Dry Eye Tests With Extraocular Signs Among 3514 Participants in the Sjögren's Syndrome International Registry. Am J Ophthalmol (2016) 0.75
Fatigue in rheumatic diseases. Eur J Rheumatol (2015) 0.75
Text-mining applied to autoimmune disease research: the Sjögren's syndrome knowledge base. BMC Musculoskelet Disord (2012) 0.75
Expression of Toll-like receptor -7 and -9 in B cell subsets from patients with primary Sjögren's syndrome. PLoS One (2015) 0.75
Multiple Roles for B-Lymphocytes in Sjogren's Syndrome. J Clin Med (2016) 0.75
Protein-Losing Gastroenteropathy Associated With Sjögren's Syndrome: First Known Case Reported Outside of Asia. ACG Case Rep J (2015) 0.75
Sjögren Syndrome and Other Causes of Sicca in Older Adults. Clin Geriatr Med (2017) 0.75
Immunomodulatory drugs: oral and systemic adverse effects. Med Oral Patol Oral Cir Bucal (2014) 0.75
Rituximab Effectiveness and Safety for Treating Primary Sjögren's Syndrome (pSS): Systematic Review and Meta-Analysis. PLoS One (2016) 0.75
[Established medications : new areas of application]. Z Rheumatol (2013) 0.75
Patient burden of Sjögren's: a comprehensive literature review revealing the range and heterogeneity of measures used in assessments of severity. RMD Open (2017) 0.75
Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther (2017) 0.75
[Reviewed for you: new criteria of Sjögren's syndrome]. Z Rheumatol (2013) 0.75
[Sjögren's syndrome]. Z Rheumatol (2014) 0.75
[Current "off label use" of methotrexate for chronic inflammatory rheumatic diseases]. Z Rheumatol (2011) 0.75
Cutaneous and Mucosal Manifestations of Sjögren's Syndrome. Clin Rev Allergy Immunol (2017) 0.75
Dual anti-neutrophil cytoplasmic antibody-related pauci-immune crescentic glomerulonephritis in a patient with Sjögren's syndrome. Rheumatol Int (2016) 0.75
Effectiveness of Traditional Chinese Medicine Compound JieDuTongLuoShengJin Granules Treatment in Primary Sjögren's Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Evid Based Complement Alternat Med (2017) 0.75
2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum (2013) 11.18
EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis (2008) 4.88
Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med (2003) 3.69
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis (2007) 3.32
Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren's syndrome. Rheumatology (Oxford) (2006) 2.57
Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses. J Dent Res (2006) 2.56
Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum (2005) 2.55
EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis (2008) 2.25
Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int (1994) 2.25
EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis (2010) 2.09
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res (1999) 2.06
[Bilateral swelling of the parotid glands as part of a systemic disease]. Ned Tijdschr Geneeskd (2003) 2.04
A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer (2010) 2.04
[Sjögren's disease]. Ned Tijdschr Geneeskd (1994) 2.00
[Oral medicine 2. Treatment of dry mouth]. Ned Tijdschr Tandheelkd (2012) 1.99
Prevention and treatment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med (2003) 1.93
[Oral health in care-dependent elderly: an inventory in a nursing home in the north of the Netherlands]. Ned Tijdschr Tandheelkd (2014) 1.92
Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process. Clin Exp Immunol (1994) 1.85
Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum (1995) 1.80
Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide. J Rheumatol (1993) 1.71
Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Ann Rheum Dis (2012) 1.68
Skin sensitivity to UVB irradiation in systemic lupus erythematosus is not related to the level of apoptosis induction in keratinocytes. Rheumatology (Oxford) (2005) 1.59
Venous thromboembolism in ANCA-associated vasculitis--incidence and risk factors. Rheumatology (Oxford) (2008) 1.56
Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study. Ann Rheum Dis (2012) 1.56
A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer (2010) 1.42
Rheumatoid arthritis and periodontitis; a possible link via citrullination. Anaerobe (2011) 1.42
Does hyperbaric oxygen therapy improve quality of life? Int J Oral Maxillofac Surg (2008) 1.41
Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat. Am J Pathol (1996) 1.37
Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Ann Rheum Dis (2004) 1.35
Interactions of surfactant protein A with influenza A viruses: binding and neutralization. J Infect Dis (1995) 1.34
Exercise therapy for trismus in head and neck cancer. Oral Oncol (2006) 1.32
Treatment concept for mandibular overdentures supported by endosseous implants: a literature review. Int J Oral Maxillofac Implants (1998) 1.29
Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis (1995) 1.29
Binding of surfactant protein A to the lipid A moiety of bacterial lipopolysaccharides. Biochem J (1994) 1.26
Eruption disturbances of permanent molars: a review. J Oral Pathol Med (1991) 1.24
Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus (2006) 1.20
Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis. Kidney Int (2006) 1.20
Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin Exp Immunol (1994) 1.15
Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology (Oxford) (2006) 1.13
Human glandular salivas: their separate collection and analysis. Eur J Oral Sci (1996) 1.13
Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Ann Rheum Dis (2008) 1.12
HMGB1 in systemic lupus Erythematosus: Its role in cutaneous lesions development. Autoimmun Rev (2010) 1.12
HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis. Autoimmun Rev (2012) 1.12
Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. Kidney Int (1998) 1.11
Prosthodontic rehabilitation of oral function in head-neck cancer patients with dental implants placed simultaneously during ablative tumour surgery: an assessment of treatment outcomes and quality of life. Int J Oral Maxillofac Surg (2007) 1.11
Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology (Oxford) (2007) 1.10
Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis (2005) 1.09
Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol (2001) 1.08
Rhino-sinusitis related to endosseous implants extending into the nasal cavity. A case report. Int J Oral Maxillofac Surg (2004) 1.08
Staphylococcal superantigens and T cell expansions in Wegener's granulomatosis. Clin Exp Immunol (2003) 1.08
Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis (2005) 1.08
Sialometry and sialochemistry: diagnostic tools for Sjögren's syndrome. Ann Rheum Dis (2001) 1.07
Parotid and submandibular/sublingual salivary flow during high dose radiotherapy. Radiother Oncol (2001) 1.07
Mandibular implants placed during ablative tumour surgery--which patients can benefit? Int J Oral Maxillofac Surg (2013) 1.07
Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res (1998) 1.05
Secondary retention of permanent molars: a histologic study. J Oral Pathol Med (1989) 1.05
Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis (2009) 1.04
Radiation induced cell loss in rat submandibular gland and its relation to gland function. Int J Radiat Biol (2000) 1.04
Sialometry and sialochemistry: a non-invasive approach for diagnosing Sjögren's syndrome. Ann Rheum Dis (2002) 1.04
Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome. Arthritis Rheum (2009) 1.03
Variation in repeated mouth-opening measurements in head and neck cancer patients with and without trismus. Int J Oral Maxillofac Surg (2008) 1.03
Coexpression of CD177 and membrane proteinase 3 on neutrophils in antineutrophil cytoplasmic autoantibody-associated systemic vasculitis: anti-proteinase 3-mediated neutrophil activation is independent of the role of CD177-expressing neutrophils. Arthritis Rheum (2009) 1.03
Intralesional infiltration of corticosteroids in the treatment of localised langerhans' cell histiocytosis of the mandible Report of known cases and three new cases. Int J Oral Maxillofac Surg (2005) 1.03
Implantology and the severely resorbed edentulous mandible. Crit Rev Oral Biol Med (2004) 1.02
Nasal high frequency ventilation in neonates with moderate respiratory insufficiency. Arch Dis Child Fetal Neonatal Ed (1998) 1.02
The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis. Osteoporos Int (2010) 1.02
In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase. Arthritis Rheum (2002) 1.01
Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res (2000) 1.01
Progression of salivary gland dysfunction in patients with Sjogren's syndrome. Ann Rheum Dis (2006) 1.00
Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol (2014) 0.99
Hypoxia inducible factor-1-alpha (HIF-1alpha) is related to both angiogenesis and inflammation in rheumatoid arthritis. Clin Exp Rheumatol (2010) 0.99
Analysis of C1q polymorphisms suggests association with systemic lupus erythematosus, serum C1q and CH50 levels and disease severity. Ann Rheum Dis (2008) 0.99
New advances in the pathogenesis of ANCA-associated vasculitides. Clin Exp Rheumatol (2009) 0.99